|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we examined the effect of EET-A, an orally active EET analog, and <i>c</i>-AUCB, an inhibitor of the EETs degrading enzyme soluble epoxide hydrolase, on the progression of post-myocardial infarction (MI) heart failure (HF) in normotensive Hannover Sprague-Dawley (HanSD) and in heterozygous <i>Ren-2</i> transgenic rats (TGR) with angiotensin II-dependent hypertension.
|
30881303 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
NADPH oxidase-derived superoxide mediates angiotensin II (Ang II)-enhanced carotid body (CB) chemoreceptor sensitivity in CHF rabbits, and tempol, the superoxide dismutase (SOD) mimetic, inhibits this Ang II- and CHF-enhanced superoxide anion effect.
|
19091790 |
2009 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Insulin insensitivity and adipokine abnormalities (the hallmarks of type 2 diabetes mellitus) are characteristic features of heart failure; conversely, neurohormonal systems activated in heart failure (norepinephrine, angiotensin II, aldosterone, and neprilysin) impair insulin sensitivity and contribute to microvascular disease in diabetes mellitus.
|
29038209 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure.
|
29744294 |
2018 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Atrial angiotensin II receptors type 1 (AT1) are downregulated in end-stage human heart failure at mRNA and protein level.
|
9302352 |
1997 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results show that angiotensin II and hypoxia, signals common to HF, result in increased LUC7L3 and RBM25 splicing regulators, increased binding of RBM25 to SCN5A mRNA, increased SCN5A splice variant abundances, decreased full-length SCN5A mRNA and protein, and decreased Na(+) current.
|
22939879 |
2013 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sensitization of the Angiotensin II AT1 Receptor Contributes to RKIP-Induced Symptoms of Heart Failure.
|
30687708 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The ChD HF subgroup showed high prevalence of bundle branch right block and, compared with the overall SHIFT population, lower systolic blood pressure; higher use of diuretics, cardiac glycosides, and antialdosterone agents; and lower use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker or target daily dose of beta-blocker.
|
29266804 |
2018 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism.
|
25036270 |
2015 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chronically elevated angiotensin II is a widely-established contributor to hypertension and heart failure via its action on the kidneys and vasculature.
|
31836539 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Substantial evidence suggests that heart failure (HF) may alter cardiac Ang-(1-12) expression and activity; this novel Ang-(1-12)/chymase axis may be the main source for angiotensin-II deleterious actions in HF.
|
31521437 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to determine the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and follow-up heart failure (HF) according to left ventricular ejection fraction (LVEF) in patients with acute myocardial infarction (AMI).
|
30924021 |
2019 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Levels of angiotensin II (Ang II), the main effector molecule of the RAS, are elevated in the failing heart and there is a substantial body of evidence indicating that this peptide contributes to changes in cardiac structure and function which ultimately lead to progressive worsening in heart failure.
|
21147120 |
2011 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Increase in inflammatory cytokines synthesis coincides with activation of microglia within PVN of angiotensin II-induced hypertensive model and myocardial infarction-induced heart failure model.
|
26874752 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition to well-known vasoactive agents such as angiotensin II, endothelin, serotonin or natriuretic peptides, the vasoconstrictor Urotensin-II (Uro-II) and the vasodilators Urocortins (UCNs) and Adrenomedullin (AM) have been implicated in the control of vascular tone and blood pressure as well as in cardiovascular disease states including congestive heart failure, atherosclerosis, coronary artery disease, and pulmonary and systemic hypertension.
|
30481494 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin II, which plays a crucial role in the myocardial remodeling process of heart failure, is generated via the angiotensin-converting enzyme and chymase pathways.
|
18641516 |
2008 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
There is convincing clinical and experimental evidence that the renin-angiotensin system (RAS) and its primary effector peptide, angiotensin II, are linked to the pathophysiology of interstitial fibrosis, cardiac remodeling, and heart failure.
|
17430683 |
2007 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
To evaluate the role of this mechanism, we assessed by an ultrasonic transient-time flow probe maximum RBF responses to renal artery infusion of angiotensin II (ANG II), norepinephrine (NE) and acetylcholine (Ach) in healthy male rats and animals with compensated and decompensated CHF.
|
30472713 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac fibrosis is a common feature in chronic hypertension patients with advanced heart failure, and endothelial-tomesenchymal transition (EndMT) is known to promote Angiotensin II (Ang II)-mediated cardiac fibrosis.
|
30670148 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Myocardial galectin-3 is upregulated upon cardiac stressors such as angiotensin II and pressure overload leading to cardiac remodeling and heart failure.
|
24789662 |
2014 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II) is a major contributor to the development of heart failure.
|
28139517 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.
|
30387679 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
This manuscript also provides a brief update on the organization of the renin-angiotensin-aldosterone system and other angiotensin-II-forming pathways with special relevance to heart failure.
|
8835867 |
1996 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, increased ACE/ACE2 ratios may induce angiotensin II over-activation and accelerate cardiac remodeling in patients with moderate to severe heart failure.
|
25869724 |
2015 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II) is known to contribute to the pathogenesis of heart failure by eliciting cardiac remodeling and dysfunction.
|
31496651 |
2019 |